TandemAI has raised $35.0M in total across 1 funding round.
TandemAI's investors include F-Prime Capital Partners.
TandemAI is a technology company that builds an integrated drug discovery platform combining AI-driven technologies, physics-based computational methods, high-performance computing, and in-house wet lab operations to accelerate preclinical drug development.[1][2][3][4] It serves over 80 biotech and pharma clients worldwide, solving the problem of high barriers to advanced tools by democratizing access through a user-friendly, cloud-based interface called TandemViz, streamlined pricing, and end-to-end solutions that improve therapeutic candidate success rates.[1][3][5][6] With over 350 employees, including 50+ top AI and computational chemistry experts, TandemAI has shown strong growth, raising $35M in Series A (2023) and $22M extension (November 2025), expanding wet lab capacity, and merging with Perpetual Medicines in July 2025.[3][6][8]
TandemAI was founded in late 2021 by Jeff He (MBA, Co-Founder and CEO) and Albert Pan (Ph.D., Co-Founder and Executive Chairman), both with deep expertise in AI, computational chemistry, and drug discovery infrastructure.[1][3] The idea emerged from recognizing barriers to advanced tools like physics-based simulations, AI models, and supercomputing, aiming to integrate them with wet labs for efficient, accessible drug discovery.[3][4] Early traction was rapid: within 15 months, it grew to ~50 clients, secured $35M Series A from investors like Qiming Venture Partners and Eight Roads (with Kan Chen joining the board), and expanded operations in the U.S. and China.[3] This momentum continued with a $22M Series A extension in November 2025 and a strategic merger with Perpetual Medicines in July 2025 to bolster physics and AI capabilities.[6][8]
TandemAI rides the AI-drug discovery wave, where computational tools promise to cut preclinical timelines and costs amid rising drug development failures (often >90% attrition rates).[3][6] Timing is ideal post-2021 AI boom, with market forces like biotech funding recovery, China-U.S. innovation hubs, and demand for integrated CROs favoring its dual-market presence (Shanghai, New York).[4] It influences the ecosystem by lowering entry barriers for smaller biotechs, fostering open-source collaboration, and enabling scalable innovation—evident in its 80+ clients and mergers like Perpetual Medicines, which amplify physics-AI synergies.[1][6][7]
TandemAI is poised to dominate integrated AI-physics drug discovery, leveraging its $57M+ Series A funding to scale wet labs, refine TandemViz, and pursue more mergers/acquisitions.[3][6][8] Trends like generative AI for molecules, multimodal data integration, and global CRO consolidation will propel growth, potentially capturing share from traditional players. Its influence may evolve into a platform leader, powering breakthroughs for underserved therapeutics and redefining accessible R&D—transforming how the world discovers life-saving drugs, just as its mission promised from day one.[1][3]
TandemAI has raised $35.0M across 1 funding round. Most recently, it raised $35.0M Series A in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $35.0M Series A | F-Prime Capital Partners |
